George Petrocheilos

WindMIL Therapeutics is Evolving We are thankful to the internal team and all the patients, clinicians, and many others who have helped us on our journey thus far in finding better treatments for cancer patients. An exciting future lies ahead for our proprietary Marrow Infiltrating Lymphocytes (MILs®) technology. Questions? Please contact us at inquiries@windmiltx.com.

CP-102 is a systemically administered, encapsulated anticancer agent that targets cancer by directly attacking one of its key hallmarks, tumor glycolysis. Cage Pharma was founded in late-2017 to develop its lead compound, CP-102, that was discovered in the laboratories of Drs. Bert Vogelstein, Kenneth Kinzler and JF Geschwind at Johns Hopkins School of medicine. The company benefits from a deep history and experience with the underlying drug compound, and has multiple published scientific manuscripts and a broad intellectual property portfolio, including recently issued composition of matter protection for its microencapsulated formulation. Cage Pharma is now ready to complete the necessary IND enabling studies and file an IND application to the FDA in early 2019. The combination of a potent anticancer agent targeting a hallmark of cancer, an excellent preclinical safety profile, and a useable built-in biomarker in the form of FDG-PET imaging, all make CP-102 an extremely promising agent and provides Cage Pharma with a unique opportunity to positively impact cancer care.

WindMIL Therapeutics is Evolving We are thankful to the internal team and all the patients, clinicians, and many others who have helped us on our journey thus far in finding better treatments for cancer patients. An exciting future lies ahead for our proprietary Marrow Infiltrating Lymphocytes (MILs®) technology. Questions? Please contact us at inquiries@windmiltx.com.

CP-102 is a systemically administered, encapsulated anticancer agent that targets cancer by directly attacking one of its key hallmarks, tumor glycolysis. Cage Pharma was founded in late-2017 to develop its lead compound, CP-102, that was discovered in the laboratories of Drs. Bert Vogelstein, Kenneth Kinzler and JF Geschwind at Johns Hopkins School of medicine. The company benefits from a deep history and experience with the underlying drug compound, and has multiple published scientific manuscripts and a broad intellectual property portfolio, including recently issued composition of matter protection for its microencapsulated formulation. Cage Pharma is now ready to complete the necessary IND enabling studies and file an IND application to the FDA in early 2019. The combination of a potent anticancer agent targeting a hallmark of cancer, an excellent preclinical safety profile, and a useable built-in biomarker in the form of FDG-PET imaging, all make CP-102 an extremely promising agent and provides Cage Pharma with a unique opportunity to positively impact cancer care.

Founded in 1995, Camden Partners is a growth equity firm that helps the management teams of enterprise software and technology-enabled companies scale their businesses. Camden has invested in 85 companies across six growth-equity funds and is known for providing creative and flexible growth capital. By focusing on the same strategy for over 25 years, the firm’s partners leverage deep domain expertise and a network of operating executives to help management teams grow revenue and cash flow. With initial equity checks between $5 million and $15 million, Camden is a preferred partner for owner-operators who are dilution sensitive.